Abstract
SB-480848 is a reversible lipoprotein-associated phospholipase A 2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.
| Original language | English |
|---|---|
| Pages (from-to) | 348-351 |
| Number of pages | 4 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 5 |
| Issue number | 3 |
| State | Published - Mar 2004 |